Analyze Diet

Blut.

Discontinued
Periodical
Hematology
Publisher:
Springer Verlag
Frequency: Monthly
Country: Germany
Language: ger
Author(s):
Deutsche Gesellschaft für Bluttransfusion., Deutsche Gesellschaft für Hämatologie., Deutsche Gesellschaft für Hämatologie und Onkologie., Deutsche Gesellschaft für Bluttransfusion und Immunhämatologie., Österreichische Gesellschaft für Hämatologie und Onkologie.
Start Year:1955 - 1990
Identifiers
ISSN:0006-5242 (Print)
0006-5242 (Linking)
NLM ID:0173401
(DNLM):B21680000(s)
(OCoLC):01536622
Coden:BLUTA9
Classification:W1 BL959
Immunoglobulin lambda-light-chain-derived amyloidosis (A lambda) in two horses.
Blut    March 1, 1989   Volume 58, Issue 3 129-132 doi: 10.1007/BF00320431
Linke RP, Trautwein G.Tumorous amyloid deposits in the nasal mucosa of two horses differed from generalized AA-amyloidosis with respect to clinical features, organ distribution, and resistance to KMnO4 treatment. Using a panel of antibodies directed against different human amyloid fibril proteins and employing the peroxidase-anti-peroxidase (PAP) technique, we showed the described equine amyloid to be A lambda-type, as demonstrated by immunohistochemical cross-reactivity. Consequently, we identified a second amyloid class in horses and showed that immunoglobulin light-chain-derived amyloid may also be present in an...
[Long-term therapy using horse anti-dog lymphocyte globulin without sensitization against horse protein].
Blut    April 1, 1977   Volume 34, Issue 4 305-316 doi: 10.1007/BF00996207
Scheel J, Duswald KH, Ring J, Seifert J, Scholz S, Brendel W.Eight mongrel dogs received a standard daily i.v. infusion of 20 mg/kg b.w. deaggregated horse-anti-dog-lymphocyte-globulin (ALG) and additional prednisolone (1 mg/kg b.w. daily i.v.) over a maximum period of 82 days following pretreatment with deaggregated normal horse IgG. No sensitization against horse protein was observed during therapy of afterwards as proved by lack of humoral antibodies against horse antigens, maintained lymphopenia, good compatibility, longterm prolongation of xenogeneic skin graft survival (85.6+/-20.6 days, n=8' untreated controls 12.5+/-1.3 days, n=4) and longterm s...